

12 November 2024

Chronic Lymphocytic Leukaemia (CLL)

1. How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?

***Answer:** The Trust Patient Administration System does not hold information on status of a newly diagnosed condition. We can only provide information on the total number of patients admitted within specific timeframes with a specific diagnosis regardless as to whether this was a first admission or subsequent admission with that diagnosis. During the time period specified there were 61 patients admitted with this diagnosis.*

2. How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment?

CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab

***Answer:** Belfast Trust does not hold this information electronically. To retrieve it would require a manual trawl through Pharmacy records, which would take more than 18 hours. This would exceed the costs limit specified in the FOI act.*

We estimate that compliance with this (element of the) request for information would exceed the appropriate costs limit. Under Section 12 of the Freedom of Information 2000, the limit has been specified as £450 and represents the estimated cost of one or more persons spending 18 hours in determining whether we hold the information, locating, retrieving and extracting this information.

3. Please complete the table below with how many newly diagnosed patients with CLL have started first-line treatment with each of the following CITs during the 6-month period February 2024 to July 2024

- FCR (fludarabine + cyclophosphamide + rituximab)
- FR (fludarabine + rituximab)
- BR (bendamustine + rituximab)
- Bendamustine monotherapy
- RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)
- Obinutuzumab ± chlorambucil

12 November 2024

- Rituximab + chlorambucil
- Ofatumumab
- Other – please specify

Note: this should only include newly diagnosed patients with CLL who have started first-line treatment during the 6-month window

Answer: Belfast Trust does not hold this information electronically. To retrieve it would require a manual trawl through Pharmacy records, which would take more than 18 hours.

Treatment option	Number of newly diagnosed patients with CLL starting first line treatment during the 6-month period February 2024 to July 2024
FCR	
FR	
BR	
Bendamustine monotherapy	
R-CHOP	
Obinutuzumab ± chlorambucil	
Rituximab + chlorambucil	
Chlorambucil monotherapy	
Rituximab monotherapy	
Ofatumumab	
Other – please specify	